You have to hand it to the private markets: they never lack for ambition. This week, reports surfaced that MSX, a venture fund, is courting two of the most polarizing names in deep tech for its third pre-IPO vehicle. On one side sits Neuralink, the brain-computer interface company with a 1,024-channel electrode thread thinner than a human hair. On the other sits Anduril, the defense contractor that wants to turn warfare into a software problem. One company wants to read your thoughts. The other wants to fly a drone swarm over them. And MSX wants to own a piece of both before the public markets get their hands on them.
Let us be clear about what we are not seeing here. The original announcement was light on specifics. It named two companies, both of which are pre-IPO, and offered a thesis that roughly translates to "AI from the human mind to the battlefield." It is a phrase that sounds like a hedge fund deck from 2021. But the more interesting question isn't whether MSX has good instincts. It's what this specific pairing reveals about how the smartest capital is positioning itself at the edge of what AI can do.
MSX is not betting on incremental improvements. They are betting on two extremes of the AI spectrum. Neuralink represents the deeply personal, biological frontier. Anduril represents the massively distributed, autonomous frontier. One is about embedding intelligence in the human body. The other is about removing humans from the kill chain. It's a contradiction that only makes sense if you believe that AI's next big unlock comes from expanding its territory into both the physical and biological worlds simultaneously.
I've spent the last few years auditing DAO governance models and token economics, but this kind of deal forces a different kind of analysis. We are not looking at a token launch or a liquidity pool. We are looking at hardware, biological interfaces, and defense contracts. This is AI's money moving from the abstract to the concrete.
On the Neuralink side, the fundamentals are getting clearer. We've seen the progress. FDA breakthrough device designation in 2025. Three patients implanted. The CONVOY trial, which links the N1 chip to an assistive robotic arm, is now in its feasibility phase. That is not just a demo. That is a clinical pathway. But here's the part of the story that gets glossed over in the hype: the company is still a research project with a revenue of zero. The valuation, estimated between $8 billion and $10 billion on the secondary market, is essentially a futures contract on the FDA's mercy. The technology is real, but the road to a commercial product is longer than the bull market believes.
Anduril is a different kind of beast. Their Lattice platform is a software-defined command system. It fuses sensor data, makes autonomous decisions, and controls a suite of hardware that includes dive drones and anti-air systems. The company's 2025 revenue was estimated at $1 billion, a 150% year-over-year increase. They signed a $250 million contract with the Pentagon's Defense Innovation Unit. And their recent $1.3 billion acquisition of Callum, a 3D printing drone company, shows they're serious about hardware integration. This is a company that is not waiting for a permission slip. It is building the infrastructure for autonomous warfare in real time.
The conventional take on this deal is that MSX is simply riding the AI wave. But I think there's a more dangerous layer to it. When you look at the ethical matrix, you can't avoid the fact that this portfolio represents two of the most ethically volatile sectors in technology. Neuralink is a human subject to device manufacturers with the power to read and modulate neural signals. Anduril is a prime contractor in the autonomous weapons supply chain.
The counter-intuitive angle is that MSX's bet isn't really about the technology. It's about the regulatory moat. Neuralink has spent more than a decade navigating FDA approval processes, animal rights lawsuits, and public scrutiny. Anduril has spent a decade embedding itself in the Department of Defense's procurement apparatus. Their moat is not their code. It's their ability to navigate the systems that most other companies can't touch.
We also need to be honest about the geopolitical backdrop. This is a portfolio that is betting on the continued militarization of the AI race. It's a hedge against a world where AI is used for both human enhancement and national security. The cynical view is that this is a classic "defense and healthcare" hedge. The more hopeful view is that it's a bet on the principle that AI's true value will be unlocked when it operates at the edge of our biological and geopolitical boundaries.
What does this mean for the rest of us? For one, it tells you that the bull market in AI is shifting. The first wave was about tools. The second wave is about infrastructure. This is the third wave: the era of the body and the battlefield. It's a shift that will require a different kind of investor, a different kind of regulator, and a different kind of ethical framework.
Code is only as strong as the trust it protects. Neuralink's code is protecting a trust that we have with our own cognition. Anduril's code is protecting a trust that we have with our own security. The question is not whether the code works. It's whether we, as a society, are ready to trust what it protects. We're not there yet. But MSX is betting that we will be, and that the wait will be worth a 3-5x return.
As you're thinking about your own portfolio, don't just look at the charts. Look at the alignment. Are you investing in companies that are building the tools for the future, or are you investing in the systems that will define the boundaries of the future? The difference is the difference between buying a pickaxe and buying a map. MSX is buying a map. The question is whether they're reading it correctly.
The most important thing to remember is that we're in a bull market that is clouded by euphoria. It's easy to get swept up in the narrative of the $100 million funding round. It's harder to look at the code and see the governance risk, the technical debt, and the long-term safety data that isn't there yet. Neuralink's three patients are a beautiful start. They are not a data set. Anduril's $1 billion in revenue is impressive. It's not a fortress. The real test will come when the market has to price in the first major safety event, the first major ethical scandal, or the first major regulatory pivot.
Trust isn't compiled, verified, and shared. It is earned through years of testing, through transparent failure, and through a demonstrated commitment to human values. When I look at this portfolio, I don't just see a smart financial move. I see a test of whether the industry can deliver on the promise that AI can be both powerful and safe. I'm hopeful, but I'm also cautious. And I think that caution is the right place to be.
It's the 21st century. The next few years will be a test of whether we can have the conversation about autonomy, about intelligence, and about our place in the loop. Are we the pilot? Are we the passenger? Or are we just the data? It's a choice. And it's one that will be made by the people who are writing the code and the people who are signing the checks. MSX is making its choice. The rest of us just have to decide how we react.
As we watch the public markets absorb this news, I'll be watching the technical indicators and the regulatory filings. But I'll also be watching the conversation. The market is betting on a future where we've accepted the brain and the battlefield as the new frontier. I'm just wondering if we're ready for what that means.
